B Cell News and Research

RSS

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

A researcher from the biomedical engineering department operated by Georgia Tech and Emory University has received a $1.5 million NIH Director's New Innovator Award to support a project aimed at reducing the incidence of stroke in children with sickle cell disease. Manu Platt, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering, will use the National Institutes of Health (NIH) funding to develop models for identifying which children with the disease are at risk for stroke.

1 Oct 2010

Researchers discover key leukemia defense mechanism

Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs).

1 Oct 2010

Albert Einstein College of Medicine receives grant to study role of proteins in health and disease

The National Institute of General Medical Sciences (NIGMS) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $30 million grant to study the structure and function of thousands of biomedically important proteins.

1 Oct 2010

Maven Semantic updates gastroesophageal reflux research database

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

1 Oct 2010

Experts provide information on H1N1 and seasonal flu at Johns Hopkins hospital

Johns Hopkins has a wide range of experts available for interviews and comments about seasonal flu, H1N1, emergency preparedness, infection control, flu transmission in children, vaccine safety, flu treatment, public health ethics, flu in cancer patients, and related public communications strategies. If you would like to interview a Johns Hopkins expert, call or e-mail the designated information officer in the list below.

1 Oct 2010

Researchers discover new factors that regulate fat formation

By creating a "map" of histone modifications in fat cells, investigators have discovered two new factors that regulate fat formation, a key step on the road to better understanding obesity, diabetes and other metabolic disorders.

1 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

Erchonia launches Zerona body-contouring laser in South East Asia

Erchonia, the global leader in low level laser healthcare applications, today announces the launch of the Zerona® body-contouring laser in South East Asia's SAARC. Erchonia Asia will exclusively market and sell the Zerona throughout the region. This new expansion coincides with the recent U.S. FDA-approval of the Zerona Laser, a non-invasive, painless treatment that guarantees the removal of fat.

30 Sep 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

NIH grants for UNC investigators to study HIV/AIDS prevention methods

Investigators at the University of North Carolina at Chapel Hill comprise one of 12 scientific teams in more than a dozen states that will receive National Institutes of Health (NIH) grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system.

30 Sep 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Study suggests H2O2 can act as anti-inflammatory compound

A major blow to the free radical theory of aging, which had lead the research in aging for more than 50 years and fuels a multimillionaire anti-aging industry has just been published by Portuguese scientists from the University of Minho. According to the theory, free radicals provoke oxidative damage and this is the cause of aging.

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

UIC develops new technique to anchor teeth back in jaw using stem cells

A new approach to anchor teeth back in the jaw using stem cells has been developed and successfully tested in the laboratory for the first time by researchers at the University of Illinois at Chicago.

30 Sep 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

ASU receives grant to unravel membrane proteins in host-pathogen interaction

Arizona State University has been awarded a $7.7 million grant for the next five years from the National Institute of General Medical Sciences, part of the National Institutes of Health, to unravel the structures of membrane proteins that play a key role in protection against infectious diseases.

30 Sep 2010

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

Mount Sinai School of Medicine received a contract for almost $16.5 million from The National Institutes of Health (NIH) and the National Heart and Lung Institute (NHLBI) through the Program of Excellence in Nanotechnology (PEN). The contract is one of four issued nationally to develop multidisciplinary research Centers with the goal of developing nanotechnology tools for diagnosing and treating heart, lung and blood diseases.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010